EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a

Table 4

Results of multivariable analyses: unique associations of relapse occurrence with follow-up MSQOL-54 PCS and MCS.

	Estimate (SE)	-value	value
One or more relapses from baseline to 12 months
MSQOL-54 PCS, = 242
≥1 relapse	−5.41 (1.92)	−2.82	0.005
MSQOL-54 MCS, = 264
Greater than secondary education	4.15 (2.00)	2.08	0.039
≥1 relapse	−4.33 (2.17)	−2.00	0.047
One or more relapses after Month 12 to 24 months^a
MSQOL-54 PCS, = 117
Age	−0.28 (0.10)	−2.76	0.006
≥1 relapse	−2.98 (2.31)	−1.29	NS
MSQOL-54 MCS, = 191
Age	−0.25 (0.11)	−2.28	0.024
Greater than secondary education	4.42 (2.15)	2.05	0.042
≥1 relapse	−3.39 (2.50)	−1.36	NS

Significant associations between relapse occurrence and follow-up MSQOL-54 PCS or MCS are highlighted in bold. The generalized linear model procedure was used; only associations at are listed except for relapse occurrence, which is listed in the table regardless of significance. All models included age, sex, highest level of education (not greater than or greater than secondary), whether naïve to DMD at study onset, whether terminated the study early, and baseline HRQoL measure score. Baseline HRQoL measure score was significant in all models.
^aThe MSQOL-54 PCS or MCS at 12 months was considered the baseline HRQoL measure score.
DMD, disease-modifying drug; HRQoL, health-related quality of life; MCS, mental health composite score; MSQOL-54, Multiple Sclerosis Quality of Life-54; NS, not statistically significant; PCS, physical health composite score; SE, standard error.